Non-Small Cell Lung Cancer Online Resource Hub

Waiting for biomarker testing results or having inadequate patient samples delays treatment for patients with non-small cell lung cancer (NSCLC). To ensure the right patients receive the right therapy at the right time, the turnaround time and accuracy of biomarker testing are key.

ASCP is committed to ensuring you have the resources, tools, and education you need to optimize the diagnosis, testing, and management of patients with NSCLC and ensure continuous quality improvement.

google-plus2 facebook < /path> twitter blogger tumblr2 reddit linkedin delicious stumbleupon mail


Featured Education

Educational activities funded through commercial support by Genentech and independent educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Pfizer, Inc.

Acknowledgements and Commercial Support

This resource page was initially developed in collaboration with the Association of Community Cancer Centers (funded by an independent educational grant from Pfizer, Inc.), and further expanded upon through a commercial sponsorship from Genentech.

Connect today with your local Genentech biomarker testing specialist at: To learn more about Genentech, please visit

ASCP does not share identifying information from the action plans with its sponsors.